DaVita Inc. $DVA Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp cut its stake in shares of DaVita Inc. (NYSE:DVA) by 13.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 118,173 shares of the company’s stock after selling 18,689 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in DaVita were worth $15,702,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. lifted its stake in DaVita by 48.1% in the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the last quarter. Mid American Wealth Advisory Group Inc. purchased a new stake in shares of DaVita during the 2nd quarter worth $36,000. Canada Pension Plan Investment Board acquired a new position in shares of DaVita during the second quarter worth $43,000. Ameritas Advisory Services LLC purchased a new position in DaVita in the second quarter valued at $47,000. Finally, Employees Retirement System of Texas acquired a new stake in DaVita in the second quarter valued at $49,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Trading Down 1.7%

DVA stock opened at $105.66 on Wednesday. The company has a market capitalization of $7.46 billion, a P/E ratio of 10.88, a PEG ratio of 0.66 and a beta of 0.99. The business has a 50 day simple moving average of $114.16 and a 200-day simple moving average of $125.81. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $179.60.

DaVita (NYSE:DVA) last released its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing the consensus estimate of $3.17 by ($0.66). The business had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.43 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.59 EPS. Research analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on DVA. Wall Street Zen cut DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. UBS Group reaffirmed a “buy” rating on shares of DaVita in a report on Monday, December 15th. TD Cowen reissued a “hold” rating on shares of DaVita in a report on Monday, November 3rd. Barclays reduced their price objective on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research report on Thursday, October 30th. Finally, Truist Financial dropped their target price on shares of DaVita from $140.00 to $128.00 and set a “hold” rating on the stock in a research report on Monday, January 5th. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $145.60.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.